Touyun Biotech Group Limited

Informe acción SEHK:1332

Capitalización de mercado: HK$608.9m

Salud financiera de hoja de balance de Touyun Biotech Group

Salud financiera controles de criterios 1/6

Touyun Biotech Group tiene un patrimonio de los accionistas total de HK$21.1M y una deuda total de HK$356.3M, lo que sitúa su ratio deuda-patrimonio en 1691%. Sus activos y pasivos totales son HK$607.3M y HK$586.3M respectivamente.

Información clave

2,227.5%

Ratio deuda-patrimonio

HK$469.39m

Deuda

Ratio de cobertura de interesesn/a
EfectivoHK$43.56m
PatrimonioHK$21.07m
Total pasivoHK$586.27m
Activos totalesHK$607.34m

Actualizaciones recientes sobre salud financiera

Recent updates

Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Apr 22
Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

Apr 08
Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

Feb 07
What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

Dec 18
Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

Sep 19
Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

Jul 28
Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Sep 13
Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt

May 18
Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Dec 24
Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

Mar 12
Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

Jan 15
If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

Jan 15
The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

Dec 11
How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (HK$162.5M) de 1332 no cubren sus pasivos a corto plazo (HK$380.7M).

Pasivo a largo plazo: Los activos a corto plazo (HK$162.5M) de 1332 no cubren sus pasivos a largo plazo (HK$205.6M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: La relación deuda neta-capital de 1332 (1520%) se considera alta.

Reducción de la deuda: El ratio deuda-patrimonio de 1332 ha crecido de 30.2% a 1691% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: 1332 tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: 1332 tiene menos de un año de cash runway si el flujo de caja libre sigue creciendo a tasas históricas de 16% cada año.


Descubre empresas con salud financiera